Loading…
Rani Therapeutics Holdings, Inc. is projected to rise to $0.9955 by 2027, a +5% move from its current price of $0.95. RANI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8923 | $0.9509 | $1.01 | +0.09% |
| May 30 | $0.8699 | $0.9518 | $1.04 | +0.18% |
| May 31 | $0.8533 | $0.9526 | $1.06 | +0.28% |
| Jun 1 | $0.8397 | $0.9535 | $1.08 | +0.37% |
| Jun 2 | $0.8279 | $0.9544 | $1.10 | +0.46% |
| Jun 3 | $0.8175 | $0.9553 | $1.12 | +0.56% |
| Jun 4 | $0.8081 | $0.9562 | $1.13 | +0.65% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8081 | $0.9562 | $1.13 | +0.65% |
| Week 2 | $0.7586 | $0.9624 | $1.22 | +1.30% |
| Week 3 | $0.7238 | $0.9686 | $1.30 | +1.96% |
| Week 4 | $0.6964 | $0.9749 | $1.36 | +2.62% |
| Week 5 | $0.6736 | $0.9812 | $1.43 | +3.29% |
| Week 6 | $0.6541 | $0.9876 | $1.49 | +3.96% |
| Week 7 | $0.6369 | $0.994 | $1.55 | +4.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with an alternative to painful injections in the United States.
Its RaniPill capsule is a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
The company’s pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. They have a collaboration agreement with ProGen Co., Ltd. for the co-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd.
to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. (RANI) is a Healthcare stock with a current price of $0.95, a market capitalization of $130.61M, and a rank of 4051. The year-by-year forecast spans 2026 through 2050, showing a path of price movement with varying averages.
The forecast places 2026 at an average of $0.95 and 2050 at an average of $1.99, with notable mid-term fluctuations and a rise into the 2030s and 2040s. In terms of returns, the range of ROIs runs from -18.1% in 2029 to 109.6% in 2050, with positive ROIs emerging from 2032 onward.
A major floor 22.7% below — a decisive break under it would weaken the trend.
The nearest floor, 8.6% below — buyers have tended to step in here.
The nearest ceiling, 16.8% above — a clean break opens room to run.
A major ceiling 46.3% above — clearing it would confirm fresh momentum.
Key RANI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RANI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.02 | Sell | $0.9913 | Sell |
| MA 10 | $1.02 | Sell | $1.00 | Sell |
| MA 20 | $0.9881 | Sell | $0.9921 | Sell |
| MA 50 | $0.957 | Sell | $1.02 | Sell |
| MA 100 | $1.14 | Sell | $1.09 | Sell |
| MA 200 | $1.15 | Sell | $1.17 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.29 | Neutral |
| Stoch RSI (14) | 22.02 | Neutral |
| CCI (20) | -34.55 | Neutral |
| Williams %R (14) | -70.80 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -1.66 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 29.20 | Neutral |
| TRIX (15) | 0.29 | Buy |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 43.38 | Neutral |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 1.00 | Sell |
| ADX (14) | 12.51 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is BEARISH. RSI14 is 50. The 50-day simple moving average is $0.957 and the 200-day simple moving average is $1.15. The near-term price supports and resistances are $0.868 and $1.11, respectively.
The 30-day price range spans from $0.6247 to $1.44, reflecting a relatively broad swing in the latest month. Volatility remains high at 100% annualized.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.735 | $0.95 | $1.21 | 0% | Neutral | |
| $0.7164 | $0.9955 | $1.50 | +5% | Neutral | |
| $0.6459 | $0.9524 | $1.52 | 0% | Neutral | |
| $0.5014 | $0.7783 | $1.30 | -18% | Bearish | |
| $0.4931 | $0.8021 | $1.40 | -16% | Bearish | |
| $0.4972 | $0.845 | $1.52 | -11% | Neutral | |
| $0.6258 | $1.11 | $2.06 | +17% | Neutral | |
| $0.6956 | $1.28 | $2.45 | +35% | Bullish | |
| $0.6171 | $1.18 | $2.32 | +25% | Bullish | |
| $0.5971 | $1.19 | $2.39 | +25% | Bullish | |
| $0.8317 | $1.85 | $4.07 | +95% | Bullish | |
| $0.896 | $1.99 | $4.58 | +110% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.735 | $0.95 | $1.13 | +0.00% |
| June 2026 | $0.8259 | $0.9905 | $1.23 | +4.26% |
| July 2026 | $0.8474 | $1.03 | $1.32 | +4.34% |
| August 2026 | $0.797 | $0.9851 | $1.28 | -4.69% |
| September 2026 | $0.7539 | $0.9422 | $1.24 | -4.35% |
| October 2026 | $0.7629 | $0.9632 | $1.29 | +2.22% |
| November 2026 | $0.7433 | $0.947 | $1.28 | -1.68% |
| December 2026 | $0.69 | $0.8867 | $1.21 | -6.36% |
Click any year to see its month-by-month RANI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RANI is projected to trade between $0.735 and $1.21, averaging $0.95 — a potential gain of 0% from today's $0.95. A consolidation phase looks the most probable path here.
Rani Therapeutics Holdings, Inc.'s 2027 outlook centres on $0.9955, within a $0.7164 to $1.50 range. That is up +5% on the projected 2026 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2028, RANI could reach as high as $1.52, with a base case around $0.9524 and support toward $0.6459 — roughly 0% from $0.95. A consolidation phase looks the most probable path here.
Expect RANI to range from $0.5014 to $1.30 through 2029. The $0.7783 average target implies a -18% move from current prices. That is -18% versus the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The RANI price prediction for 2030 points to an average of $0.8021 (low $0.4931, high $1.40) — a potential decline of -16% on today's $0.95. Expect choppier, lower action through this leg of the cycle.
In 2031, RANI is projected to trade between $0.4972 and $1.52, averaging $0.845 — a potential decline of -11% from today's $0.95. That is up +5% on the projected 2030 average. Price action looks broadly range-bound.
Rani Therapeutics Holdings, Inc.'s 2032 outlook centres on $1.11, within a $0.6258 to $2.06 range. That is up +31% on the projected 2031 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, RANI could reach as high as $2.45, with a base case around $1.28 and support toward $0.6956 — roughly +35% from $0.95. Momentum favours further upside here.
Expect RANI to range from $0.6171 to $2.32 through 2034. The $1.18 average target implies a +25% move from current prices. That is -8% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The RANI price prediction for 2035 points to an average of $1.19 (low $0.5971, high $2.39) — a potential gain of +25% on today's $0.95. Momentum favours further upside here.
In 2040, RANI is projected to trade between $0.8317 and $4.07, averaging $1.85 — a potential gain of +95% from today's $0.95. That is up +55% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Rani Therapeutics Holdings, Inc.'s 2050 outlook centres on $1.99, within a $0.896 to $4.58 range. That is up +8% on the projected 2040 average. That marks a +110% change versus current levels. Momentum favours further upside here.
Investing $1,000 in RANI today (≈ 1,052.631579 RANI) could be worth
$2,096.02
+$1,096.02 (+110%) by 2050 · US Dollar
Based on the average projected RANI price of $1.99 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RANIwould be worth at today's price.
$1,000 invested in RANI on May 27, 2025 (≈ 1,610.305979 RANI) would be worth
$1,529.79
+$529.79 (+53.0%) today · 1.53× · US Dollar
Based on a RANI entry price of $0.621 vs. today's $0.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.09 | $871.56 | -12.8% |
| 1 month ago | $0.89 | $1,067.42 | +6.7% |
| 3 months ago | $1.38 | $688.41 | -31.2% |
| 6 months ago | $1.6 | $593.75 | -40.6% |
| 1 year ago | $0.621 | $1,529.79 | +53.0% |
| All time (4.8y) ago | $11 | $86.36 | -91.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RANI forecast.
Our base-case forecast reaches $1.90 around 2050.
Implied market cap at $1.90: $213.54M
The multi-year forecast shows a dip in the late 2020s followed by a recovery and a pronounced uptrend into the 2030s and beyond. In 2032 the average price is forecast at $1.11 with a 16.8% ROI, rising to an average of $1.28 in 2033 (ROI 35.1%), then moderating to $1.18 in 2034 (ROI 24.7%) and $1.19 in 2035 (ROI 25.4%). By 2040 the average price is projected at $1.85 with a 94.5% ROI, and by 2050 the average is $1.99 with a 109.6% ROI.
Earlier years show more subdued activity, with 2026 at $0.95 (ROI 0%), 2027 at $0.9955 (4.8%), 2028 at $0.9524 (0.3%), and a dip in 2029 at $0.7783 (ROI -18.1%), followed by 2030 at $0.8021 (ROI -15.6%) and 2031 at $0.845 (ROI -11.1%). These figures illustrate a potential long-term upside with substantial uncertainty and volatility. These are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $0.8021 with a minimum of $0.4931 and a maximum of $1.40, and a ROI of -15.6%. The sentiment is BEARISH.
Forecasts show a range of outcomes: 2029 average price $0.7783 with ROI -18.1% and 2030 average $0.8021 with ROI -15.6%, followed by positive ROIs in 2032 (16.8%), 2033 (35.1%), 2040 (94.5%), and 2050 (109.6%). These are estimates and involve uncertainty and volatility.
Yes. The maximums in the forecast reach above $2 in several years: 2033 max $2.45, 2034 max $2.32, and 2035 max $2.39.
The nearer-term view is BEARISH with RSI 14 at 50. The 50-day SMA is $0.957 and the 200-day SMA is $1.15. Support is at $0.868 and resistance at $1.11, with a 30-day range from $0.6247 to $1.44 and annualized volatility of 100%.
The current price is $0.95 and the market capitalization is $130.61M. The stock is ranked 4051.
Rani Therapeutics Holdings, Inc. Community Discussion
0Share your Rani Therapeutics Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.